Browsing Tag
ASCO 2026
9 posts
Avacta (AIM: AVCT) raises £9m at no discount days after ASCO cancer data
Avacta (AIM: AVCT) raised £9m at no discount just before a 30 June bond trigger, days after AVA6000 cancer data. Is this a turnaround or another clock ticking?
GT Medical Technologies’ GammaTile Phase 3 data strengthens case for surgery-time radiation in brain metastases
GammaTile’s Phase 3 data challenges delayed brain radiation after surgery. The bigger question is whether hospitals will change workflows.
Whitehawk Therapeutics (Nasdaq: WHWK) stock focus sharpens as ASCO 2026 data support SEZ6 ADC strategy in small cell lung cancer
Find out how Whitehawk Therapeutics’ SEZ6 data at ASCO 2026 could shape its HWK-206 ADC strategy in small cell lung cancer.
Can Kelun-Biotech and Merck turn sac-TMT into the first ADC plus immunotherapy standard in front-line lung cancer?
Merck needs life after Keytruda. Kelun-Biotech’s sac-TMT lung cancer data may show how the next oncology cycle takes shape.
Dizal Pharmaceutical deepens NSCLC pipeline case as DZD6008 and golidocitinib data sharpen ASCO 2026 focus
Read how Dizal’s ASCO 2026 NSCLC data for DZD6008 and golidocitinib could reshape its lung cancer pipeline strategy today!
How the TIGeR-PaC sub-study could influence future thinking around chemotherapy tolerability and precision delivery
RenovoRx’s TIGeR-PaC sub-study highlights how targeted chemotherapy delivery could reshape pancreatic cancer treatment strategy. Read more.
Why clinicians and regulators are closely watching AstraZeneca’s rare disease and solid tumor pipeline strategy
Why AstraZeneca’s ASCO 2026 rare disease and solid tumor pipeline strategy is drawing major clinical and regulatory attention. Read more.
Karyopharm Therapeutics (KPTI) tees up ASCO 2026 readout as SENTRY trial shifts myelofibrosis debate
Karyopharm is taking its Phase 3 SENTRY myelofibrosis data to ASCO 2026. Read why the late-breaking slot matters for KPTI and selinexor now.
Why platinum-resistant ovarian cancer remains a high-stakes proving ground for CDH6-targeted ADCs
Can SIM0505 change NextCure’s oncology outlook? Read why platinum-resistant ovarian cancer is the key test case for 2026.